2型糖尿病合并颅内动脉瘤患者控糖治疗中甘精胰岛素联合瑞格列奈的应用价值  

Application Value of Insulin Glargine Combined with Repaglinide in Glu⁃cose Control Treatment of Patients with Type 2 Diabetes Mellitus Compli⁃cated with Intracranial Aneurysms

作　　者：贺莎 黄巧妹 张静 HE Sha;HUANG Qiaomei;ZHANG Jing(Department of Neurosurgery,73rd Army Group Hospital of the PLA,Xiamen 361001,Fujian,China)

机构地区：[1]中国人民解放军陆军第七十三集团军医院神经外科,福建厦门361001

出　　处：《糖尿病新世界》2025年第2期71-74,共4页Diabetes New World

摘　　要：目的探究甘精胰岛素与瑞格列奈联用于2型糖尿病(type 2 diabetes mellitus,T2DM)合并颅内动脉瘤患者治疗中对控糖效果的影响。方法回顾性选取2023年1月—2024年5月中国人民解放军陆军第七十三集团军医院收治的104例T2DM合并颅内动脉瘤患者的临床资料,根据不同治疗手段分为对照组(行甘精胰岛素治疗)、研究组(行甘精胰岛素联合瑞格列奈治疗),各52例。比较两组不良反应发生情况、血糖水平及临床疗效。结果治疗12周后,研究组餐后2 h血糖、空腹血糖及糖化血红蛋白水平相比于对照组均更低,差异均有统计学意义(P均<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论甘精胰岛素治疗T2DM合并颅内动脉瘤患者基础上加入瑞格列奈,用药安全性较高且控糖效果更佳,提升临床疗效。Objective To explore the effect of insulin glargine combined with repaglinide on glucose control in pa-tients with type 2 diabetes mellitus(T2DM)complicated with intracranial aneurysms.Methods The clinical data of 104 patients with T2DM complicated with intracranial aneurysms admitted to the 73rd Army Group Hospital of the PLA from January 2023 to May 2024 were retrospectively selected.According to different treatment methods,they were divided into control group(treated with insulin glargine)and study group(treated with insulin glargine combined with repaglinide),with 52 cases in each group.The incidence of adverse reactions,blood glucose levels and clinical ef-ficacy were compared between the two groups.Results After 12 weeks of treatment,the levels of 2-hour postprandial blood glucose,fasting blood glucose and glycated hemoglobin A1c in the study group were lower than those in the con-trol group,and the differences were statistically significant(all P<0.05).The total effective rate of treatment in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Repa-glinide is added on the basis of insulin glargine in the treatment of T2DM patients with intracranial aneurysms.The safety of medication is high and the effect of glucose control is better,and the clinical efficacy is improved.

关 键 词：2型糖尿病 颅内动脉瘤 甘精胰岛素 瑞格列奈 控糖效果 

分 类 号：R587.1[医药卫生—内分泌]